Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 4 Road to targeting mutant p53

Published byHendri Hartanto Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 4 Road to targeting mutant p53"— Presentation transcript:

1 Figure 4 Road to targeting mutant p53
Figure 4 | Road to targeting mutant p53. This timeline shows the major breakthroughs that have fuelled efforts to target mutant p53 for anticancer therapy. Milestones relating to efforts to target wild-type (WT) p53 are outside the scope of this Review and are not included. DN, dominant-negative; GOF, gain-of-function; LFS, Li–Fraumeni syndrome; siRNA, short interfering RNA; Tg, transgenic. Sabapathy, K. & Lane, D. P. (2017) Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 4 Road to targeting mutant p53"

Similar presentations

Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 3 Intracranial targeting of high-grade gliomas

Figure 3 Intracranial targeting of high-grade gliomas
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Chimeric antigen receptor (CAR) structures

Figure 1 Chimeric antigen receptor (CAR) structures
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Similar presentations

Ads by Google